-
Something wrong with this record ?
Trial Watch: Toll-like receptor agonists in cancer immunotherapy
M. Smith, E. García-Martínez, MR. Pitter, J. Fucikova, R. Spisek, L. Zitvogel, G. Kroemer, L. Galluzzi,
Language English Country United States
Document type Journal Article, Review
- Publication type
- Journal Article MeSH
- Review MeSH
Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.
Department of Medicine and Immunology Program Memorial Sloan Kettering Cancer Center New York NY USA
Hematology and Oncology Department Hospital Universitario Morales Meseguer Murcia Spain
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19001453
- 003
- CZ-PrNML
- 005
- 20190115111451.0
- 007
- ta
- 008
- 190107s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/2162402X.2018.1526250 $2 doi
- 035 __
- $a (PubMed)30524908
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Smith, Melody $u Department of Medicine and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- 245 10
- $a Trial Watch: Toll-like receptor agonists in cancer immunotherapy / $c M. Smith, E. García-Martínez, MR. Pitter, J. Fucikova, R. Spisek, L. Zitvogel, G. Kroemer, L. Galluzzi,
- 520 9_
- $a Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate clinically useful immunostimulatory effects has been extensively investigated over the past few years. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for cancer therapy.
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a García-Martínez, Elena $u Hematology and Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain.
- 700 1_
- $a Pitter, Michael R $u Department of Medicine and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- 700 1_
- $a Fucikova, Jitka $u Sotio a.c., Prague, Czech Republic. Department of Immunology, 2nd Faculty of Medicine, University Hospital Motol, Charles University, Prague, Czech Republic.
- 700 1_
- $a Spisek, Radek $u Sotio a.c., Prague, Czech Republic. Department of Immunology, 2nd Faculty of Medicine, University Hospital Motol, Charles University, Prague, Czech Republic.
- 700 1_
- $a Zitvogel, Laurence $u INSERM, U1015, Villejuif, France. Gustave Roussy Comprehensive Cancer Institute, Villejuif, France. Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France. Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France.
- 700 1_
- $a Kroemer, Guido $u Université Paris Descartes/ Paris V, Paris, France. Université Pierre et Marie Curie/Paris VI, Paris, France. INSERM, U1138, Paris, France. Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France. Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden. Pôle de Biologie, Hopitâl Européen George Pompidou, AP-HP; Paris, France.
- 700 1_
- $a Galluzzi, Lorenzo $u Université Paris Descartes/ Paris V, Paris, France. Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA. Sandra and Edward Meyer Cancer Center, New York, NY, USA.
- 773 0_
- $w MED00190079 $t Oncoimmunology $x 2162-4011 $g Roč. 7, č. 12 (2018), s. e1526250
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30524908 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20190115111702 $b ABA008
- 999 __
- $a ind $b bmc $g 1364098 $s 1039576
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 7 $c 12 $d e1526250 $e 20181011 $i 2162-4011 $m Oncoimmunology $n Oncoimmunology $x MED00190079
- LZP __
- $a Pubmed-20190107
